Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXNX Axonics	$70.98	$70.61	$67.60 ▼ $71.05	$3.63B	0.82	429,281 shs	N/A
CSII Cardiovascular Systems	$20.00	$19.98	$12.26 ▼ $20.57	$843.96M	0.74	765,906 shs	4,300 shs
INO Inovio Pharmaceuticals	$1.36 -2.2%	$1.93	$1.30 ▼ $12.33	$49.88M	1.31	810,646 shs	1.78 million shs
LUNG Pulmonx	$2.90 +9.4%	$3.05	$2.50 ▼ $9.37	$116.75M	0.45	312,552 shs	1.79 million shs
SILK Silk Road Medical	$27.49	$27.31	$6.08 ▼ $27.51	$1.12B	1.53	1.20 million shs	N/A

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXNX Axonics	0.00%	0.00%	0.00%	0.00%	+4.81%
CSII Cardiovascular Systems	0.00%	0.00%	0.00%	0.00%	0.00%
INO Inovio Pharmaceuticals	-2.16%	-5.23%	-35.85%	-15.53%	-85.34%
LUNG Pulmonx	+9.43%	+4.50%	-11.04%	-44.76%	-54.33%
SILK Silk Road Medical	0.00%	0.00%	0.00%	0.00%	+1.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXNX Axonics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CSII Cardiovascular Systems	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	4.1313 of 5 stars	3.3	3.0	0.0	4.4	2.5	0.0	1.3
LUNG Pulmonx	3.5997 of 5 stars	3.3	5.0	0.0	0.0	2.6	3.3	0.6
SILK Silk Road Medical	0.4658 of 5 stars	1.0	0.0	0.0	4.3	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXNX Axonics	2.00	Hold	N/A	N/A
CSII Cardiovascular Systems	0.00	N/A	N/A	N/A
INO Inovio Pharmaceuticals	2.60	Moderate Buy	$8.80	547.06% Upside
LUNG Pulmonx	2.63	Moderate Buy	$11.53	297.41% Upside
SILK Silk Road Medical	2.00	Hold	$27.50	0.04% Upside

Current Analyst Ratings Breakdown

Latest SILK, LUNG, AXNX, CSII, and INO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	INO Inovio Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$5.00
5/22/2025	LUNG Pulmonx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.50 ➝ $4.15
5/14/2025	INO Inovio Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$5.00 ➝ $5.00
5/14/2025	INO Inovio Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $13.00
5/1/2025	LUNG Pulmonx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/1/2025	LUNG Pulmonx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$10.00 ➝ $9.00
5/1/2025	LUNG Pulmonx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXNX Axonics	$366.38M	9.90	$0.13 per share	561.96	$12.59 per share	5.64
CSII Cardiovascular Systems	$239.84M	3.52	N/A	N/A	$6.12 per share	3.27
INO Inovio Pharmaceuticals	$220K	226.69	N/A	N/A	$1.90 per share	0.72
LUNG Pulmonx	$83.79M	1.39	N/A	N/A	$2.17 per share	1.34
SILK Silk Road Medical	$177.13M	6.31	N/A	N/A	$3.88 per share	7.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXNX Axonics	-$6.09M	-$0.12	N/A	80.66	N/A	-1.31%	0.36%	0.31%	N/A
CSII Cardiovascular Systems	-$36.93M	-$0.97	N/A	N/A	N/A	-15.79%	-15.39%	-11.93%	N/A
INO Inovio Pharmaceuticals	-$107.25M	-$3.19	N/A	N/A	N/A	N/A	-136.93%	-89.99%	8/6/2025 (Estimated)
LUNG Pulmonx	-$56.39M	-$1.44	0.00	N/A	N/A	-65.27%	-63.69%	-34.94%	7/30/2025 (Estimated)
SILK Silk Road Medical	-$55.74M	-$1.37	N/A	N/A	N/A	-29.53%	-37.30%	-21.57%	N/A

Latest SILK, LUNG, AXNX, CSII, and INO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	LUNG Pulmonx	-$0.40	N/A	N/A	N/A	$23.46 million	N/A
5/13/2025	Q1 2025	INO Inovio Pharmaceuticals	-$0.74	-$0.51	+$0.23	-$0.51	$0.01 million	$0.07 million
5/7/2025	Q1 2025	LUNG Pulmonx	-$0.37	-$0.36	+$0.01	-$0.36	$22.03 million	$22.54 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXNX Axonics	N/A	N/A	N/A	N/A	N/A
CSII Cardiovascular Systems	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LUNG Pulmonx	N/A	N/A	N/A	N/A	N/A
SILK Silk Road Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXNX Axonics	N/A	8.16	6.40
CSII Cardiovascular Systems	0.08	6.04	4.92
INO Inovio Pharmaceuticals	N/A	2.63	2.63
LUNG Pulmonx	0.38	4.97	4.29
SILK Silk Road Medical	0.49	7.63	6.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXNX Axonics	99.48%
CSII Cardiovascular Systems	86.61%
INO Inovio Pharmaceuticals	26.79%
LUNG Pulmonx	91.04%
SILK Silk Road Medical	N/A

Insider Ownership

Company	Insider Ownership
AXNX Axonics	1.85%
CSII Cardiovascular Systems	3.80%
INO Inovio Pharmaceuticals	2.30%
LUNG Pulmonx	6.80%
SILK Silk Road Medical	3.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXNX Axonics	610	51.11 million	50.16 million	Optionable
CSII Cardiovascular Systems	780	42.20 million	40.59 million	Optionable
INO Inovio Pharmaceuticals	320	36.67 million	35.83 million	Optionable
LUNG Pulmonx	250	40.26 million	37.52 million	Optionable
SILK Silk Road Medical	410	40.63 million	37.91 million	Optionable

SILK, LUNG, AXNX, CSII, and INO Headlines

Recent News About These Companies

Photos show where US and China have sent hospital ships

June 18, 2025 | msn.com

Three Andritz spunlace lines for Alear Silk Road

April 25, 2025 | innovationintextiles.comI

ANDRITZ To Supply Three Spunlace Lines To Alear Silk Road New Materials, China

April 25, 2025 | textileworld.comT

2,200-year-old grave in China contains 'Red Princess of the Silk Road' whose teeth were painted with a toxic substance

March 12, 2025 | msn.com

Xinjiang a front-runner in BRI medical cooperation

March 7, 2025 | chinadaily.com.cnC

Endologix Appoints Andrew Davis as Chief Commercial Officer

March 3, 2025 | businesswire.com

China’s Belt and Road Initiative: The art of exploiting threats and opportunities

February 21, 2025 | tehrantimes.comT

Boston Scientific ramped up headcount, real estate footprint in 2024

February 21, 2025 | bizjournals.com

Trump pardons Silk Road founder Ross Ulbricht for online drug scheme

January 23, 2025 | reuters.com

Trump pardons Ross Ulbricht, creator of online black market for illegal drugs

January 23, 2025 | msn.com

Trump pardons founder of Silk Road website

January 23, 2025 | msn.com

Silk Road founder Ross Ulbricht went to prison a libertarian hero. Trump just set him free.

January 22, 2025 | msn.com

Trump pardons online drug marketplace Silk Road founder, Austin native Ross Ulbricht

January 22, 2025 | msn.com

Who Is Ross Ulbricht? What To Know About ‘Silk Road’ Drug Marketplace Founder Pardoned By Trump.

January 22, 2025 | msn.com

Trump pardons Ross Ulbricht, founder of online drug market Silk Road

January 22, 2025 | msn.com

Trump Pardons Creator of Silk Road Drug Marketplace

January 22, 2025 | nytimes.com

Chinese, Pakistani firms sign $250m MoUs

January 19, 2025 | tribune.com.pkT

MoUs worth $250m signed with Chinese medical companies

January 19, 2025 | dawn.comD

Pakistani, Chinese companies ink $250mn MoUs to boost medical sector

January 18, 2025 | brecorder.comB

Pakistani, Chinese companies ink $250 million MoUs to boost medical sector

January 18, 2025 | business-standard.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Southwest Airlines: Short Interest Plunges—Should You Buy?
By Gabriel Osorio-Mazilli | June 17, 2025
View Southwest Airlines: Short Interest Plunges—Should You Buy?

SILK, LUNG, AXNX, CSII, and INO Company Descriptions

Axonics NASDAQ:AXNX

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Cardiovascular Systems NASDAQ:CSII

Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.

Inovio Pharmaceuticals NASDAQ:INO

$1.36 -0.03 (-2.16%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$1.38 +0.01 (+1.10%)

As of 07/11/2025 07:59 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Pulmonx NASDAQ:LUNG

$2.90 +0.25 (+9.43%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$2.94 +0.04 (+1.38%)

As of 07/11/2025 07:57 PM Eastern

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Silk Road Medical NASDAQ:SILK

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time